ZIFA 01
Alternative Names: ZIFA-01Latest Information Update: 28 May 2023
At a glance
- Originator Tianjin Institute of Pharmaceutical Research
- Developer Peking University; Tianjin Institute of Pharmaceutical Research
- Class Antithrombotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Thrombosis in China (PO, Tablet)